Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the compensation committee of the company's board of directors granted one new employee options to purchase a total of 5,550 shares of the company's common stock at an exercise price per share of $11.07, which was the closing price on february 21, 2025, and.
RCUS Ratings Summary
RCUS Quant Ranking